| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Carcinoma, Non-Small-Cell Lung | 28 | 2018 | 896 | 4.74 | Why? |
| Lung Neoplasms | 37 | 2020 | 3228 | 3.24 | Why? |
| Antineoplastic Agents | 29 | 2021 | 3550 | 3.12 | Why? |
| Clinical Trials, Phase I as Topic | 11 | 2021 | 242 | 2.54 | Why? |
| B7-H1 Antigen | 14 | 2018 | 541 | 2.42 | Why? |
| Biomarkers, Tumor | 18 | 2018 | 1314 | 2.09 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 16 | 2018 | 1573 | 1.98 | Why? |
| Neoplasms | 49 | 2021 | 17251 | 1.88 | Why? |
| Programmed Cell Death 1 Receptor | 14 | 2018 | 724 | 1.81 | Why? |
| Protein Kinase Inhibitors | 10 | 2018 | 1585 | 1.75 | Why? |
| ErbB Receptors | 6 | 2018 | 320 | 1.54 | Why? |
| Piperazines | 3 | 2018 | 445 | 1.25 | Why? |
| Endometrial Neoplasms | 2 | 2017 | 120 | 1.23 | Why? |
| Immunotherapy | 15 | 2018 | 2421 | 1.17 | Why? |
| Erlotinib Hydrochloride | 4 | 2018 | 48 | 1.14 | Why? |
| Antineoplastic Agents, Immunological | 8 | 2019 | 830 | 1.10 | Why? |
| Pemetrexed | 3 | 2017 | 32 | 1.05 | Why? |
| Disease-Free Survival | 14 | 2018 | 1654 | 0.95 | Why? |
| Carcinoma, Squamous Cell | 6 | 2018 | 902 | 0.93 | Why? |
| Response Evaluation Criteria in Solid Tumors | 3 | 2017 | 37 | 0.93 | Why? |
| Cisplatin | 3 | 2017 | 209 | 0.93 | Why? |
| Neoplastic Cells, Circulating | 3 | 2019 | 68 | 0.88 | Why? |
| Carboplatin | 2 | 2017 | 76 | 0.86 | Why? |
| Antibodies, Monoclonal | 15 | 2019 | 8041 | 0.82 | Why? |
| Genetic Markers | 2 | 2017 | 318 | 0.79 | Why? |
| Genes, erbB | 1 | 2018 | 2 | 0.78 | Why? |
| Pyrimidines | 3 | 2017 | 1557 | 0.77 | Why? |
| Mutation | 17 | 2019 | 12376 | 0.76 | Why? |
| Immunoconjugates | 1 | 2019 | 90 | 0.75 | Why? |
| Indazoles | 2 | 2017 | 77 | 0.73 | Why? |
| Medical Oncology | 6 | 2021 | 3826 | 0.71 | Why? |
| Telomere | 2 | 2010 | 146 | 0.70 | Why? |
| Sulfones | 2 | 2017 | 66 | 0.70 | Why? |
| Receptor, ErbB-2 | 4 | 2018 | 267 | 0.70 | Why? |
| Cryptogenic Organizing Pneumonia | 1 | 2017 | 35 | 0.68 | Why? |
| Thiazolidinediones | 1 | 2017 | 70 | 0.68 | Why? |
| Sulfoxides | 1 | 2017 | 43 | 0.68 | Why? |
| Genetic Testing | 3 | 2018 | 395 | 0.67 | Why? |
| DNA Repair | 4 | 2018 | 114 | 0.67 | Why? |
| Paclitaxel | 1 | 2017 | 124 | 0.66 | Why? |
| Bortezomib | 1 | 2017 | 125 | 0.66 | Why? |
| Maximum Tolerated Dose | 8 | 2019 | 65 | 0.63 | Why? |
| Bevacizumab | 1 | 2017 | 149 | 0.63 | Why? |
| Industry | 1 | 2019 | 347 | 0.59 | Why? |
| Patient Selection | 6 | 2021 | 4560 | 0.59 | Why? |
| Drug Resistance, Neoplasm | 6 | 2019 | 447 | 0.59 | Why? |
| Academies and Institutes | 1 | 2019 | 539 | 0.58 | Why? |
| Therapies, Investigational | 1 | 2017 | 235 | 0.56 | Why? |
| Patient Reported Outcome Measures | 2 | 2020 | 912 | 0.56 | Why? |
| Sirolimus | 3 | 2017 | 240 | 0.53 | Why? |
| Carcinoma | 1 | 2017 | 256 | 0.53 | Why? |
| Quinazolines | 4 | 2017 | 126 | 0.51 | Why? |
| Dose-Response Relationship, Drug | 12 | 2019 | 3776 | 0.50 | Why? |
| Cell Cycle Proteins | 2 | 2019 | 297 | 0.48 | Why? |
| Protein-Tyrosine Kinases | 3 | 2017 | 158 | 0.47 | Why? |
| Otorhinolaryngologic Diseases | 1 | 2017 | 491 | 0.42 | Why? |
| Nausea | 4 | 2018 | 457 | 0.41 | Why? |
| Oral Ulcer | 1 | 2011 | 70 | 0.41 | Why? |
| Kaplan-Meier Estimate | 9 | 2018 | 4260 | 0.39 | Why? |
| Sulfonamides | 2 | 2018 | 1294 | 0.39 | Why? |
| Precancerous Conditions | 1 | 2010 | 108 | 0.39 | Why? |
| Treatment Outcome | 29 | 2020 | 51732 | 0.39 | Why? |
| Whole Exome Sequencing | 4 | 2019 | 437 | 0.38 | Why? |
| Genomics | 4 | 2018 | 3118 | 0.38 | Why? |
| Proliferating Cell Nuclear Antigen | 2 | 2019 | 18 | 0.38 | Why? |
| Neoplasm Metastasis | 5 | 2018 | 682 | 0.38 | Why? |
| Indoles | 1 | 2017 | 1243 | 0.37 | Why? |
| Molecular Targeted Therapy | 8 | 2018 | 1579 | 0.37 | Why? |
| Acrylamides | 2 | 2018 | 40 | 0.36 | Why? |
| Neoplasms, Radiation-Induced | 1 | 2009 | 60 | 0.36 | Why? |
| Carcinoma, Papillary | 1 | 2009 | 76 | 0.36 | Why? |
| DNA Damage | 1 | 2010 | 285 | 0.36 | Why? |
| Thioxanthenes | 1 | 2007 | 1 | 0.35 | Why? |
| Lymphocytes, Tumor-Infiltrating | 2 | 2018 | 130 | 0.35 | Why? |
| Breast | 1 | 2010 | 290 | 0.35 | Why? |
| Aniline Compounds | 2 | 2018 | 120 | 0.34 | Why? |
| Cyclin-Dependent Kinases | 2 | 2017 | 124 | 0.33 | Why? |
| Neoplasm Staging | 9 | 2018 | 1999 | 0.32 | Why? |
| Aged | 53 | 2021 | 215776 | 0.32 | Why? |
| Deoxycytidine | 2 | 2017 | 116 | 0.32 | Why? |
| Middle Aged | 59 | 2021 | 270681 | 0.31 | Why? |
| Benzamides | 3 | 2018 | 421 | 0.31 | Why? |
| Drug Administration Schedule | 3 | 2017 | 2324 | 0.31 | Why? |
| Antibodies, Monoclonal, Humanized | 8 | 2021 | 9335 | 0.30 | Why? |
| Humans | 107 | 2021 | 930598 | 0.29 | Why? |
| Phosphatidylinositol 3-Kinases | 3 | 2017 | 347 | 0.29 | Why? |
| Disease Progression | 7 | 2018 | 13580 | 0.29 | Why? |
| Signal Transduction | 5 | 2018 | 7207 | 0.28 | Why? |
| Female | 66 | 2021 | 380317 | 0.28 | Why? |
| High-Throughput Nucleotide Sequencing | 6 | 2018 | 3633 | 0.28 | Why? |
| Male | 66 | 2021 | 367725 | 0.28 | Why? |
| Thyroid Neoplasms | 1 | 2009 | 422 | 0.26 | Why? |
| Pyrazoles | 4 | 2017 | 1791 | 0.26 | Why? |
| Aged, 80 and over | 25 | 2021 | 88759 | 0.25 | Why? |
| Retreatment | 3 | 2018 | 186 | 0.25 | Why? |
| Proto-Oncogene Proteins p21(ras) | 3 | 2017 | 100 | 0.24 | Why? |
| Biological Products | 1 | 2017 | 2331 | 0.24 | Why? |
| Adult | 44 | 2021 | 244371 | 0.24 | Why? |
| Fatigue | 3 | 2018 | 2479 | 0.24 | Why? |
| Hematologic Neoplasms | 3 | 2021 | 2105 | 0.24 | Why? |
| Lymphoma | 2 | 2017 | 522 | 0.23 | Why? |
| Exome | 3 | 2018 | 207 | 0.23 | Why? |
| Otorhinolaryngologic Neoplasms | 1 | 2001 | 15 | 0.23 | Why? |
| DNA Mutational Analysis | 3 | 2019 | 581 | 0.23 | Why? |
| Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2017 | 29 | 0.22 | Why? |
| Endonucleases | 2 | 2018 | 68 | 0.22 | Why? |
| Brain Neoplasms | 2 | 2018 | 669 | 0.22 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 3 | 2020 | 1261 | 0.21 | Why? |
| Survival Rate | 5 | 2017 | 9206 | 0.21 | Why? |
| Breast Neoplasms | 4 | 2018 | 3633 | 0.21 | Why? |
| Cell Count | 2 | 2018 | 228 | 0.21 | Why? |
| Natural Cytotoxicity Triggering Receptor 2 | 1 | 2019 | 4 | 0.21 | Why? |
| France | 10 | 2021 | 12074 | 0.20 | Why? |
| Antimetabolites, Antineoplastic | 2 | 2017 | 99 | 0.20 | Why? |
| TOR Serine-Threonine Kinases | 2 | 2013 | 385 | 0.20 | Why? |
| Linitis Plastica | 1 | 2018 | 1 | 0.19 | Why? |
| DNA-Binding Proteins | 3 | 2018 | 469 | 0.19 | Why? |
| Acetanilides | 1 | 2018 | 9 | 0.19 | Why? |
| Survival Analysis | 9 | 2018 | 7592 | 0.19 | Why? |
| Receptor, ErbB-3 | 1 | 2018 | 7 | 0.19 | Why? |
| Receptor Protein-Tyrosine Kinases | 2 | 2017 | 243 | 0.18 | Why? |
| Clinical Studies as Topic | 1 | 2019 | 118 | 0.18 | Why? |
| Enhancer of Zeste Homolog 2 Protein | 1 | 2018 | 40 | 0.18 | Why? |
| CD27 Ligand | 1 | 2017 | 17 | 0.18 | Why? |
| Neoplasms, Experimental | 1 | 2018 | 67 | 0.18 | Why? |
| DNA, Neoplasm | 1 | 2017 | 56 | 0.18 | Why? |
| Gene Amplification | 2 | 2017 | 85 | 0.18 | Why? |
| Predictive Value of Tests | 9 | 2018 | 9537 | 0.18 | Why? |
| Germ-Line Mutation | 1 | 2018 | 86 | 0.18 | Why? |
| Gastrointestinal Stromal Tumors | 1 | 2018 | 84 | 0.18 | Why? |
| Proto-Oncogene Proteins c-met | 1 | 2017 | 40 | 0.18 | Why? |
| Prostatic Neoplasms, Castration-Resistant | 1 | 2019 | 109 | 0.17 | Why? |
| Adenocarcinoma | 2 | 2017 | 651 | 0.17 | Why? |
| Antibodies, Anti-Idiotypic | 1 | 2017 | 93 | 0.17 | Why? |
| Cytotoxicity, Immunologic | 1 | 2019 | 287 | 0.17 | Why? |
| NAD | 1 | 2018 | 73 | 0.17 | Why? |
| Evidence-Based Medicine | 2 | 2021 | 3228 | 0.17 | Why? |
| Stomach | 1 | 2018 | 141 | 0.17 | Why? |
| Microsatellite Instability | 1 | 2017 | 57 | 0.17 | Why? |
| Benzodiazepines | 1 | 2019 | 163 | 0.17 | Why? |
| Molecular Imaging | 1 | 2018 | 110 | 0.17 | Why? |
| Lymphopenia | 2 | 2021 | 2669 | 0.17 | Why? |
| Health Status Indicators | 2 | 2018 | 341 | 0.17 | Why? |
| Soft Tissue Neoplasms | 1 | 2018 | 131 | 0.16 | Why? |
| Diarrhea | 4 | 2018 | 2743 | 0.16 | Why? |
| Proteasome Inhibitors | 1 | 2017 | 127 | 0.16 | Why? |
| Image-Guided Biopsy | 1 | 2018 | 185 | 0.16 | Why? |
| Myocardial Contraction | 1 | 2018 | 123 | 0.16 | Why? |
| Meningeal Neoplasms | 1 | 2017 | 48 | 0.16 | Why? |
| Biliary Tract Neoplasms | 1 | 2017 | 93 | 0.16 | Why? |
| HLA-A2 Antigen | 1 | 2017 | 134 | 0.16 | Why? |
| Oropharyngeal Neoplasms | 1 | 2018 | 138 | 0.16 | Why? |
| Lymphoma, B-Cell | 1 | 2018 | 166 | 0.16 | Why? |
| Metabolome | 1 | 2021 | 624 | 0.16 | Why? |
| Anorexia | 1 | 2017 | 194 | 0.16 | Why? |
| Prognosis | 16 | 2021 | 32490 | 0.16 | Why? |
| Drug Dosage Calculations | 1 | 2017 | 243 | 0.16 | Why? |
| Young Adult | 18 | 2021 | 93724 | 0.15 | Why? |
| Glioblastoma | 1 | 2018 | 187 | 0.15 | Why? |
| Antibody Specificity | 2 | 2018 | 1328 | 0.15 | Why? |
| Monitoring, Physiologic | 1 | 2007 | 1956 | 0.15 | Why? |
| Precision Medicine | 4 | 2018 | 1477 | 0.15 | Why? |
| Small Cell Lung Carcinoma | 1 | 2017 | 133 | 0.15 | Why? |
| Vomiting | 2 | 2018 | 722 | 0.15 | Why? |
| Heterocyclic Compounds, 3-Ring | 1 | 2018 | 275 | 0.15 | Why? |
| Pruritus | 1 | 2017 | 215 | 0.14 | Why? |
| Sarcoma | 1 | 2018 | 290 | 0.14 | Why? |
| Physicians, Family | 1 | 2018 | 208 | 0.14 | Why? |
| Hodgkin Disease | 1 | 2017 | 204 | 0.14 | Why? |
| Janus Kinase 1 | 1 | 2017 | 254 | 0.14 | Why? |
| Tumor Suppressor Protein p53 | 1 | 2017 | 310 | 0.14 | Why? |
| Proto-Oncogene Proteins | 1 | 2017 | 340 | 0.14 | Why? |
| Cell-Free Nucleic Acids | 1 | 2017 | 271 | 0.14 | Why? |
| Placebos | 1 | 2017 | 629 | 0.14 | Why? |
| Comparative Genomic Hybridization | 3 | 2018 | 33 | 0.14 | Why? |
| Pyridines | 2 | 2017 | 680 | 0.13 | Why? |
| Stomatitis | 1 | 2013 | 57 | 0.13 | Why? |
| In Situ Hybridization, Fluorescence | 2 | 2017 | 207 | 0.13 | Why? |
| Blood Proteins | 1 | 2017 | 551 | 0.13 | Why? |
| Career Choice | 1 | 2019 | 498 | 0.13 | Why? |
| Transcription Factors | 1 | 2019 | 784 | 0.13 | Why? |
| Central Nervous System | 1 | 2018 | 701 | 0.12 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2017 | 782 | 0.12 | Why? |
| Fecal Microbiota Transplantation | 1 | 2017 | 372 | 0.12 | Why? |
| Gene Rearrangement | 3 | 2017 | 84 | 0.12 | Why? |
| Immune System Diseases | 1 | 2017 | 410 | 0.12 | Why? |
| Electrocardiography | 1 | 2007 | 3957 | 0.12 | Why? |
| Molecular Diagnostic Techniques | 3 | 2017 | 4239 | 0.12 | Why? |
| Stomach Neoplasms | 1 | 2018 | 477 | 0.12 | Why? |
| Pyridones | 1 | 2018 | 738 | 0.12 | Why? |
| Clinical Trials as Topic | 3 | 2021 | 7330 | 0.12 | Why? |
| Immunoenzyme Techniques | 2 | 2016 | 448 | 0.11 | Why? |
| Ovarian Neoplasms | 1 | 2017 | 465 | 0.11 | Why? |
| Cancer Survivors | 1 | 2018 | 588 | 0.11 | Why? |
| Drug Monitoring | 1 | 2019 | 1408 | 0.11 | Why? |
| Chemotherapy, Adjuvant | 3 | 2018 | 606 | 0.11 | Why? |
| Gene Expression Profiling | 3 | 2018 | 3788 | 0.11 | Why? |
| Drug Industry | 1 | 2019 | 689 | 0.11 | Why? |
| Practice Guidelines as Topic | 3 | 2020 | 15421 | 0.11 | Why? |
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2017 | 869 | 0.10 | Why? |
| Prospective Studies | 9 | 2018 | 43301 | 0.10 | Why? |
| Neoplasm Recurrence, Local | 1 | 2017 | 1063 | 0.10 | Why? |
| Head and Neck Neoplasms | 2 | 2019 | 1568 | 0.10 | Why? |
| Drug Interactions | 1 | 2017 | 1653 | 0.10 | Why? |
| Adenocarcinoma, Follicular | 1 | 2009 | 21 | 0.10 | Why? |
| Tissue Array Analysis | 1 | 2009 | 75 | 0.10 | Why? |
| Quinolines | 1 | 2013 | 403 | 0.10 | Why? |
| Papillomavirus Infections | 1 | 2018 | 861 | 0.10 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2018 | 1731 | 0.09 | Why? |
| Everolimus | 1 | 2011 | 215 | 0.09 | Why? |
| Killer Cells, Natural | 1 | 2019 | 2093 | 0.09 | Why? |
| Cetuximab | 2 | 2018 | 35 | 0.09 | Why? |
| Early Detection of Cancer | 2 | 2018 | 1956 | 0.09 | Why? |
| Transcriptome | 2 | 2018 | 3466 | 0.09 | Why? |
| Neoplasm Invasiveness | 1 | 2010 | 582 | 0.09 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.09 | Why? |
| DNA Copy Number Variations | 2 | 2018 | 84 | 0.09 | Why? |
| Histones | 1 | 2010 | 371 | 0.08 | Why? |
| Exons | 2 | 2018 | 158 | 0.08 | Why? |
| Enzyme Inhibitors | 1 | 2018 | 1881 | 0.08 | Why? |
| Immunomodulation | 1 | 2016 | 1472 | 0.08 | Why? |
| Time Factors | 9 | 2021 | 31397 | 0.08 | Why? |
| Genetic Variation | 2 | 2018 | 3919 | 0.08 | Why? |
| Gene Expression | 1 | 2017 | 3332 | 0.08 | Why? |
| Anemia | 1 | 2013 | 789 | 0.08 | Why? |
| Area Under Curve | 1 | 2013 | 2564 | 0.08 | Why? |
| Mouthwashes | 1 | 2011 | 432 | 0.08 | Why? |
| Double-Blind Method | 1 | 2017 | 5988 | 0.08 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.08 | Why? |
| Tumor Microenvironment | 2 | 2018 | 264 | 0.08 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.08 | Why? |
| Health Care Rationing | 1 | 2020 | 2558 | 0.08 | Why? |
| Proportional Hazards Models | 4 | 2020 | 6543 | 0.07 | Why? |
| Pneumonectomy | 2 | 2018 | 278 | 0.07 | Why? |
| Carcinoma, Small Cell | 1 | 2004 | 16 | 0.07 | Why? |
| Virus Shedding | 1 | 2021 | 5834 | 0.07 | Why? |
| Lymphocytes | 1 | 2017 | 3056 | 0.07 | Why? |
| Smoking | 1 | 2018 | 3358 | 0.07 | Why? |
| Telomerase | 1 | 2004 | 45 | 0.07 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.07 | Why? |
| Gastrointestinal Microbiome | 1 | 2017 | 1961 | 0.07 | Why? |
| Sequence Analysis, DNA | 3 | 2018 | 2830 | 0.07 | Why? |
| Autoimmune Diseases | 1 | 2018 | 1996 | 0.07 | Why? |
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 1014 | 0.07 | Why? |
| Echocardiography | 1 | 2018 | 3661 | 0.07 | Why? |
| Serum Albumin | 2 | 2017 | 571 | 0.06 | Why? |
| Recurrence | 3 | 2017 | 3675 | 0.06 | Why? |
| Retrospective Studies | 13 | 2018 | 105322 | 0.06 | Why? |
| Neoplasm Proteins | 2 | 2018 | 501 | 0.06 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.06 | Why? |
| Phenotype | 3 | 2018 | 4037 | 0.06 | Why? |
| Computational Biology | 1 | 2018 | 4514 | 0.06 | Why? |
| Immunohistochemistry | 3 | 2018 | 2275 | 0.06 | Why? |
| Drug Repositioning | 1 | 2021 | 5683 | 0.06 | Why? |
| Micrococcaceae | 1 | 2021 | 72 | 0.06 | Why? |
| Immunoassay | 1 | 2018 | 4485 | 0.06 | Why? |
| Referral and Consultation | 1 | 2018 | 4816 | 0.06 | Why? |
| Anti-Inflammatory Agents | 1 | 2021 | 6153 | 0.06 | Why? |
| Internet | 1 | 2020 | 6204 | 0.06 | Why? |
| Anticarcinogenic Agents | 1 | 2001 | 25 | 0.06 | Why? |
| Multivariate Analysis | 3 | 2017 | 5440 | 0.06 | Why? |
| Genetic Predisposition to Disease | 4 | 2018 | 4027 | 0.06 | Why? |
| Biomarkers | 3 | 2021 | 23361 | 0.06 | Why? |
| Risk Factors | 8 | 2020 | 71621 | 0.06 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.06 | Why? |
| Chromosome Aberrations | 1 | 2001 | 54 | 0.06 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2018 | 5837 | 0.05 | Why? |
| Reproducibility of Results | 4 | 2018 | 11304 | 0.05 | Why? |
| Immunologic Factors | 1 | 2017 | 4206 | 0.05 | Why? |
| Heart Diseases | 1 | 2018 | 3503 | 0.05 | Why? |
| Neutrophils | 1 | 2017 | 5476 | 0.05 | Why? |
| Animals | 6 | 2019 | 78931 | 0.05 | Why? |
| Fever | 1 | 2017 | 7795 | 0.05 | Why? |
| Mice, Inbred NOD | 1 | 2019 | 134 | 0.05 | Why? |
| Acneiform Eruptions | 1 | 2018 | 4 | 0.05 | Why? |
| Tumor Cells, Cultured | 1 | 2019 | 254 | 0.05 | Why? |
| Oximes | 1 | 2018 | 51 | 0.05 | Why? |
| Mice, SCID | 1 | 2019 | 225 | 0.05 | Why? |
| Tubulin | 1 | 2018 | 67 | 0.05 | Why? |
| Quality of Life | 2 | 2017 | 9820 | 0.05 | Why? |
| L-Lactate Dehydrogenase | 2 | 2017 | 1995 | 0.05 | Why? |
| Ploidies | 1 | 2018 | 5 | 0.05 | Why? |
| Combined Modality Therapy | 2 | 2018 | 3395 | 0.05 | Why? |
| RNA, Neoplasm | 1 | 2018 | 34 | 0.05 | Why? |
| Receptors, Notch | 1 | 2018 | 59 | 0.05 | Why? |
| Xenograft Model Antitumor Assays | 1 | 2019 | 274 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2017 | 6331 | 0.05 | Why? |
| Nicotinamide Phosphoribosyltransferase | 1 | 2018 | 30 | 0.05 | Why? |
| Verrucomicrobia | 1 | 2017 | 6 | 0.05 | Why? |
| Ipilimumab | 1 | 2018 | 102 | 0.05 | Why? |
| Receptors, CCR | 1 | 2017 | 26 | 0.05 | Why? |
| Vaccination | 2 | 2021 | 19050 | 0.05 | Why? |
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 15 | 0.04 | Why? |
| Chromosomes, Human, Pair 8 | 1 | 2017 | 25 | 0.04 | Why? |
| Severity of Illness Index | 3 | 2017 | 48226 | 0.04 | Why? |
| Oncogene Fusion | 1 | 2017 | 1 | 0.04 | Why? |
| Platinum Compounds | 1 | 2017 | 20 | 0.04 | Why? |
| Entropy | 1 | 2017 | 52 | 0.04 | Why? |
| Stress, Mechanical | 1 | 2018 | 143 | 0.04 | Why? |
| Asthenia | 1 | 2018 | 107 | 0.04 | Why? |
| Alternative Splicing | 1 | 2018 | 82 | 0.04 | Why? |
| Cell Cycle Checkpoints | 1 | 2018 | 126 | 0.04 | Why? |
| Sensitivity and Specificity | 2 | 2017 | 22971 | 0.04 | Why? |
| Genetic Heterogeneity | 1 | 2017 | 77 | 0.04 | Why? |
| Receptors, CXCR3 | 1 | 2017 | 159 | 0.04 | Why? |
| Lactams | 1 | 2017 | 50 | 0.04 | Why? |
| Enterobacteriaceae | 1 | 2021 | 395 | 0.04 | Why? |
| Liquid Biopsy | 1 | 2017 | 114 | 0.04 | Why? |
| Mice, Nude | 1 | 2018 | 340 | 0.04 | Why? |
| Tissue Distribution | 1 | 2019 | 483 | 0.04 | Why? |
| Odds Ratio | 2 | 2020 | 5861 | 0.04 | Why? |
| Biomechanical Phenomena | 1 | 2018 | 291 | 0.04 | Why? |
| CTLA-4 Antigen | 1 | 2018 | 282 | 0.04 | Why? |
| Cancer Vaccines | 1 | 2018 | 136 | 0.04 | Why? |
| Heterozygote | 1 | 2018 | 249 | 0.04 | Why? |
| Homozygote | 1 | 2018 | 230 | 0.04 | Why? |
| DNA, Bacterial | 1 | 2021 | 835 | 0.04 | Why? |
| Interleukin-12 | 1 | 2017 | 156 | 0.04 | Why? |
| Protein Isoforms | 1 | 2018 | 347 | 0.04 | Why? |
| Lactams, Macrocyclic | 1 | 2017 | 130 | 0.04 | Why? |
| Biphenyl Compounds | 1 | 2018 | 249 | 0.04 | Why? |
| Biomedical Research | 1 | 2017 | 5270 | 0.04 | Why? |
| Global Health | 1 | 2020 | 13911 | 0.04 | Why? |
| Anilides | 1 | 2017 | 105 | 0.04 | Why? |
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 43 | 0.04 | Why? |
| Injections, Subcutaneous | 1 | 2018 | 647 | 0.04 | Why? |
| CD4 Antigens | 1 | 2017 | 306 | 0.04 | Why? |
| Aminopyridines | 1 | 2017 | 121 | 0.04 | Why? |
| Age of Onset | 1 | 2018 | 557 | 0.04 | Why? |
| Morpholines | 1 | 2018 | 351 | 0.04 | Why? |
| Neoplasm Grading | 1 | 2017 | 400 | 0.04 | Why? |
| Software | 2 | 2018 | 2501 | 0.04 | Why? |
| Febrile Neutropenia | 1 | 2018 | 179 | 0.04 | Why? |
| Clone Cells | 1 | 2016 | 312 | 0.04 | Why? |
| Metagenome | 1 | 2017 | 268 | 0.04 | Why? |
| Observer Variation | 1 | 2018 | 622 | 0.04 | Why? |
| Lymphocyte Count | 2 | 2017 | 4758 | 0.04 | Why? |
| Case-Control Studies | 2 | 2018 | 17671 | 0.04 | Why? |
| Serum Albumin, Human | 1 | 2017 | 265 | 0.04 | Why? |
| Inflammation | 1 | 2018 | 13255 | 0.04 | Why? |
| Mutation Rate | 1 | 2017 | 382 | 0.04 | Why? |
| Metabolomics | 1 | 2021 | 921 | 0.04 | Why? |
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 372 | 0.04 | Why? |
| Cardiotoxicity | 1 | 2018 | 365 | 0.03 | Why? |
| Antigens, Neoplasm | 1 | 2016 | 230 | 0.03 | Why? |
| Polypharmacy | 1 | 2017 | 347 | 0.03 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2018 | 801 | 0.03 | Why? |
| Tomography, X-Ray Computed | 2 | 2018 | 25144 | 0.03 | Why? |
| Blood-Brain Barrier | 1 | 2018 | 531 | 0.03 | Why? |
| Proto-Oncogene Proteins B-raf | 1 | 2016 | 179 | 0.03 | Why? |
| Infection Control | 2 | 2020 | 23131 | 0.03 | Why? |
| Mice | 3 | 2019 | 21357 | 0.03 | Why? |
| Genome, Human | 1 | 2018 | 400 | 0.03 | Why? |
| Immunotherapy, Adoptive | 1 | 2018 | 524 | 0.03 | Why? |
| Viremia | 1 | 2021 | 1020 | 0.03 | Why? |
| Colonic Neoplasms | 1 | 2018 | 295 | 0.03 | Why? |
| Drug Eruptions | 1 | 2018 | 319 | 0.03 | Why? |
| Probability | 1 | 2018 | 923 | 0.03 | Why? |
| Adolescent | 5 | 2021 | 86841 | 0.03 | Why? |
| Infusions, Intravenous | 1 | 2018 | 1224 | 0.03 | Why? |
| Oncologists | 1 | 2020 | 877 | 0.03 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.03 | Why? |
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2017 | 449 | 0.03 | Why? |
| Urologic Neoplasms | 1 | 2018 | 348 | 0.03 | Why? |
| Gene Frequency | 1 | 2018 | 1210 | 0.03 | Why? |
| Patient Outcome Assessment | 1 | 2017 | 707 | 0.03 | Why? |
| Multimodal Imaging | 1 | 2017 | 534 | 0.03 | Why? |
| Logistic Models | 2 | 2018 | 9089 | 0.03 | Why? |
| Hematologic Tests | 1 | 2017 | 521 | 0.03 | Why? |
| Pandemics | 7 | 2021 | 389249 | 0.03 | Why? |
| Withholding Treatment | 1 | 2018 | 798 | 0.03 | Why? |
| Radiotherapy | 1 | 2017 | 608 | 0.03 | Why? |
| Age Factors | 3 | 2018 | 21039 | 0.03 | Why? |
| DNA | 1 | 2018 | 778 | 0.03 | Why? |
| Protein Multimerization | 1 | 2018 | 1336 | 0.03 | Why? |
| Alleles | 1 | 2018 | 1557 | 0.03 | Why? |
| A549 Cells | 1 | 2018 | 2066 | 0.03 | Why? |
| Databases, Genetic | 1 | 2018 | 1127 | 0.03 | Why? |
| Cell Proliferation | 1 | 2019 | 1973 | 0.03 | Why? |
| Sequence Alignment | 1 | 2018 | 2109 | 0.03 | Why? |
| Image Interpretation, Computer-Assisted | 1 | 2018 | 665 | 0.03 | Why? |
| Prostatic Neoplasms | 1 | 2004 | 1637 | 0.03 | Why? |
| Infant | 2 | 2017 | 30274 | 0.03 | Why? |
| Carcinoma, Renal Cell | 1 | 2018 | 545 | 0.03 | Why? |
| Administration, Oral | 1 | 2018 | 2340 | 0.03 | Why? |
| Child, Preschool | 2 | 2017 | 36283 | 0.03 | Why? |
| Disease Management | 2 | 2018 | 6841 | 0.02 | Why? |
| Safety | 1 | 2017 | 1583 | 0.02 | Why? |
| Follow-Up Studies | 2 | 2019 | 17020 | 0.02 | Why? |
| Kidney Neoplasms | 1 | 2018 | 832 | 0.02 | Why? |
| Immunity | 1 | 2020 | 2651 | 0.02 | Why? |
| Sequence Analysis, RNA | 1 | 2018 | 2290 | 0.02 | Why? |
| Lung | 1 | 2018 | 31049 | 0.02 | Why? |
| Apoptosis | 1 | 2019 | 2335 | 0.02 | Why? |
| Geriatric Assessment | 1 | 2017 | 1372 | 0.02 | Why? |
| Biopsy | 1 | 2017 | 2811 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2019 | 5542 | 0.02 | Why? |
| Risk | 1 | 2020 | 5288 | 0.02 | Why? |
| Interferon Type I | 1 | 2021 | 2789 | 0.02 | Why? |
| Immunization Programs | 1 | 2020 | 2006 | 0.02 | Why? |
| Equipment Design | 1 | 2018 | 3095 | 0.02 | Why? |
| Risk Assessment | 1 | 2011 | 25439 | 0.02 | Why? |
| Melanoma | 1 | 2018 | 1229 | 0.02 | Why? |
| Amino Acid Sequence | 1 | 2018 | 6049 | 0.02 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.02 | Why? |
| Consensus | 1 | 2020 | 6345 | 0.02 | Why? |
| Survivors | 1 | 2017 | 2619 | 0.02 | Why? |
| Neoplasms, Hormone-Dependent | 1 | 2004 | 25 | 0.02 | Why? |
| Child | 2 | 2017 | 70012 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2018 | 3607 | 0.02 | Why? |
| Feces | 1 | 2017 | 4235 | 0.02 | Why? |
| Health Status | 1 | 2017 | 3259 | 0.02 | Why? |
| Clinical Decision-Making | 1 | 2017 | 3755 | 0.02 | Why? |
| Forecasting | 1 | 2017 | 4492 | 0.02 | Why? |
| Computer Simulation | 1 | 2018 | 4982 | 0.02 | Why? |
| Ambulatory Care | 1 | 2020 | 4947 | 0.02 | Why? |
| Cell Line | 1 | 2018 | 12040 | 0.01 | Why? |
| Nasopharynx | 1 | 2021 | 10224 | 0.01 | Why? |
| Blotting, Western | 1 | 2004 | 863 | 0.01 | Why? |
| Aging | 1 | 2017 | 3581 | 0.01 | Why? |
| Algorithms | 1 | 2018 | 7346 | 0.01 | Why? |
| Magnetic Resonance Imaging | 1 | 2017 | 6551 | 0.01 | Why? |
| T-Lymphocytes | 1 | 2017 | 6670 | 0.01 | Why? |
| Models, Theoretical | 1 | 2017 | 6659 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2017 | 10649 | 0.01 | Why? |
| Registries | 1 | 2018 | 12327 | 0.01 | Why? |
| Catalytic Domain | 1 | 2004 | 1757 | 0.01 | Why? |
| Health Services Accessibility | 1 | 2020 | 10697 | 0.01 | Why? |
| Infant, Newborn | 1 | 2017 | 23105 | 0.01 | Why? |
| Cytokines | 1 | 2018 | 15010 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2017 | 10083 | 0.01 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.01 | Why? |
| Public Health | 1 | 2020 | 16359 | 0.01 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.01 | Why? |
| Environmental Exposure | 1 | 2004 | 1558 | 0.01 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.01 | Why? |
| Telemedicine | 1 | 2020 | 25032 | 0.01 | Why? |